ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

ODAC Advice: Avoid ESAs In Curative Settings, Require Patients To Sign Informed Consent.

March 14, 2008

Leptin Could Be Indicator Of Breast Cancer Risk

April 25, 2003

FASEB urges 10 percent increase for NIH in FY 2005.

January 23, 2004

Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say

December 8, 1995

Bayh To Receive ACCC Annual Award

February 8, 1980

Sharp Increase In Cancer Mortality Could Bring Drastic Program Changes; All 1975 Data Needed

December 12, 1975